Steven Skolsky

Quintiles Transnational Corp. provides biopharmaceutical development and commercial outsourcing services. It offers product development and integrated healthcare services, including commercial and observational solutions. The company was founded by Dennis B. Gillings and Gary Koch in September 1990 and is headquartered in Durham, NC.

Elligo Health Research, Inc. provides clinical research services. It offers Direct approach and IntElligo Research Stack clinical technology ? a complete standards-based technology solution that delivers better patients and improved real-time data. The company was founded by John Gary Potthoff and Chad Moore on March 1, 2016 and is headquartered in Austin, TX.

Clinipace, Inc. provides digital contract research solutions. The firm operates as a digital contract research organization that assists life science firms in developing and executing regulatory strategies, clinical development, and post-approval research. Its service areas encompass clinical monitoring, data management, medical affairs and writing, patient recruitment, study feasibility, and site selection and management. The company was founded by Ronald G. Marks, Christopher K. Porter, and Jeff Lewis Williams in 2003 and is headquartered in Morrisville, NC.

Quintiles Transnational Holdings, Inc. engages in biopharmaceutical development and commercial outsourcing. It operates through the Product Development and Integrated Healthcare Services segments. The Product Development segments provide project management and clinical monitoring, clinical trial support services, strategic planning and design, and consulting services. The Integrated Healthcare Services segments provide commercial services, communications and engagement services, real-world and late phase research, and other healthcare solutions. The company was founded by Dr. Gillings in 1982 and is headquartered in Durham, NC.

Sequoia Pharmaceuticals discovers and develops unique treatments for viral diseases including HIV/AIDS and HCV-induced hepatitis with a focus on the growing global problem of drug-resistant disease. Most new anti-viral drugs were designed to block the most prevalent form of a pathogen, but these drugs become less potent due to the emergence of drug-resistant mutations. Sequoia's is to discover and develop new antiviral which are active against the most prevalent form of the virus but also anticipates the emergence of drug resistance forms thereby maintaining potency over time. Sequoia's differentiating approach is to identify a constellation of atomic interaction points which are necessary and sufficient for enzymatic function. Sequoia's protease inhibitors have been designed to interact preferentially with only these atoms, thus allowing non-critical mutations to occur without resulting in a decrease in drug potency. The foundation of Sequoia's novel Resistant-Repellent™ technology is a drug discovery tool that enhances the efficiency with which drugs are designed. It is based on an understanding of the chemical and physical nature of the molecular targets, the enzymes and receptors to which drugs bind, combined with an understanding of the molecular mechanisms that cause drug resistance. Sequoia is also discovering and developing a unique series of pharmacokinetic enhancers (PKEs) to work in combination with its own, and its partners', antiviral therapies. These sets of molecules improve the PK of existing therapeutics and reduce interpatient variability. This represents a unique approach to an important need in HIV treatment today. Sequoia is also looking to extend this novel PKE approach to other areas. Its PKEs are designed to inhibit a particular CYP isozyme and therefore change the metabolism of a co-administered therapeutic agent. The combination of PK Enhancer and the therapeutic agent enables reduced dosage and less frequent administration of the therapeutic agent.